betway必威登陆网址 (betway.com )学报››2023,Vol. 44››Issue (4): 286-290.DOI:10.3969/j.issn.2097-0005.2023.04.009

• 临床研究 •上一篇下一篇

基于炎性因子、疼痛介质探究前列腺增生治疗中HolEP与PKERP的疗效差异

汪生辉()

  1. 聊城市第二人民医院泌尿外科,山东 聊城 252600
  • 收稿日期:2022-12-06出版日期:2023-04-25发布日期:2023-05-15
  • 作者简介:汪生辉,学士,主治医师,研究方向:泌尿外科、男科, E-mail:1250205634@qq.com

The difference between HolEP and PKERP in the treatment of benign prostatic hyperplasia based on inflammatory factors and pain mediators

Shenghui WANG()

  1. Urology Department,The Second People’s Hospital of Liaocheng,Liaocheng 252600,China
  • Received:2022-12-06Online:2023-04-25Published:2023-05-15

摘要:

目的研究经尿道前列腺钬激光剜除术(holmium laser enucleation of the prostate,HoLEP)与经尿道双极等离子前列腺剜除术(transurethral bipolar plasma kinetic enucleation and resection of the prostate,PKERP)治疗前列腺增生的疗效差异。方法选取2020年8月至2022年8月聊城市第二人民医院泌尿外科收治的前列腺增生患者90例,随机分为HoLEP组(45例,HoLEP治疗)、PKERP组(45例,PKERP治疗),比较两组围术期指标,测量术前、术后血清炎性因子、疼痛介质水平及最大尿流率,评估患者术后疼痛情况,统计术后并发症。结果HoLEP组术中出血量、膀胱冲洗天数、住院天数、导尿管留置天数均显著少于PKERP组;术后1周HoLEP组最大尿流率高于PKERP组;术后1天HoLEP组血清白介素-2(interleukin-2,IL-2)、白介素-6(interleukin-6,IL-6)均显著低于PKERP组(P< 0.05);术后1天HoLEP组血清前列腺素E2(prostaglandin E2,PGE2)、5-羟色胺(5-hydroxy tryptamine, 5-HT)水平显著低于PKERP组(P< 0.05);术后1天、2天、3天HoLEP组疼痛视觉模拟评分法(visual analogue scale,VAS)均显著低于PKERP组,差异均有统计学意义(P< 0.05);HoLEP组并发症发生率显著低于PKERP组(P< 0.05)。结论HoLEP治疗前列腺增生,可显著下调患者术后炎性因子及疼痛介质水平,减轻患者术后疼痛感,且具有创伤性小、并发症少的优点。

关键词:前列腺增生,经尿道前列腺钬激光剜除术,经尿道双极等离子前列腺剜除术,炎性因子,疼痛介质

Abstract:

ObjectiveTo study the effects of transurethral holmium laser enucleation of prostate (HoLEP) and transurethral bipolar plasma enucleation of prostate (PKERP) on inflammatory factors and pain mediators in patients with benign prostatic hyperplasia.MethodsNinety patients with benign prostatic hyperplasia admitted to our hospital from August 2020 to August 2022 were selected and randomly divided into HoLEP group (45 cases, HoLEP treatment) and PKERP group (45 cases, PKERP treatment), and the perioperative indicators of the two groups were compared, preoperative and postoperative serum inflammatory factors, pain mediator levels and maximum urinary flow rate were measured, postoperative pain was evaluate, and postoperative complications were detected.ResultsThe amount of intraoperative bleeding, days of bladder flushing, days of hospitalization and days of indwelling catheter in HoLEP group were significantly lower than those in PKERP group (P< 0.05); The maximum urinary flow rate in HoLEP group was higher than that in PKERP group in the 1st week after operation, (P< 0.05); the levels of serum interleukin-2 (IL-2) and interleukin-6 (IL-6) in HoLEP group were significantly lower than those in PKERP group on the 1st day after operation (P< 0.05); The serum 5-hydroxytryptamine (5-TH) and prostaglandin E2 (PGE2) levels in HoLEP group were significantly lower than those in PKERP group 1 day after operation (P< 0.05); The scores of visual analogue of pain (VAS) in the HoLEP group were significantly lower than those in the PKERP group on the 1st, 2nd and 3rd day after operation (P< 0.05); The incidence of complications in HoLEP group was significantly lower than that in PKERP group (P< 0.05).ConclusionCompared with PKERP, HoLEP can significantly reduce the levels of inflammatory factors and pain mediators in patients with benign prostatic hyperplasia after operation, relieve the patients’ postoperative pain, and has the advantages of less trauma and fewer complications.

Key words:benign prostatic hyperplasia,transurethral holmium laser enucleation of prostate,transurethral bipolar plasma enucleation of prostate,inflammatory factors,pain mediator